822 related articles for article (PubMed ID: 26847547)
21. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice.
Rolla S; Alchera E; Imarisio C; Bardina V; Valente G; Cappello P; Mombello C; Follenzi A; Novelli F; Carini R
Clin Sci (Lond); 2016 Feb; 130(3):193-203. PubMed ID: 26558403
[TBL] [Abstract][Full Text] [Related]
22. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
23. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients.
Tiniakos DG
Gastroenterol Clin Biol; 2009; 33(10-11):930-9. PubMed ID: 19646834
[TBL] [Abstract][Full Text] [Related]
24. [Nonalcoholic fatty liver disease].
Lemoine M; Serfaty L
Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
[TBL] [Abstract][Full Text] [Related]
25. Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation.
Chatzigeorgiou A; Chung KJ; Garcia-Martin R; Alexaki VI; Klotzsche-von Ameln A; Phieler J; Sprott D; Kanczkowski W; Tzanavari T; Bdeir M; Bergmann S; Cartellieri M; Bachmann M; Nikolakopoulou P; Androutsellis-Theotokis A; Siegert G; Bornstein SR; Muders MH; Boon L; Karalis KP; Lutgens E; Chavakis T
Hepatology; 2014 Oct; 60(4):1196-210. PubMed ID: 24845056
[TBL] [Abstract][Full Text] [Related]
26. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
27. The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise.
Wu L; Gao X; Guo Q; Li J; Yao J; Yan K; Xu Y; Jiang X; Ye D; Guo J
Hepatol Int; 2020 Sep; 14(5):652-666. PubMed ID: 32880077
[TBL] [Abstract][Full Text] [Related]
28. CD8
Breuer DA; Pacheco MC; Washington MK; Montgomery SA; Hasty AH; Kennedy AJ
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G211-G224. PubMed ID: 31709830
[TBL] [Abstract][Full Text] [Related]
29. [The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases].
Bao Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Jul; 25(7):553-556. PubMed ID: 29056000
[TBL] [Abstract][Full Text] [Related]
30. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
31. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.
Su Q; Kumar V; Sud N; Mahato RI
Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222
[TBL] [Abstract][Full Text] [Related]
32. [Cholesterol metabolism and non-alcoholic steatohepatitis].
Ma ZZ; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2016 Aug; 24(8):623-627. PubMed ID: 27788713
[TBL] [Abstract][Full Text] [Related]
33. Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.
Zhao C; Ji G; Zhao X; Ma T; Li Y; Wu W; Zhou L
Comb Chem High Throughput Screen; 2024 May; ():. PubMed ID: 38803181
[TBL] [Abstract][Full Text] [Related]
34. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
35. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
Sundaram V; Morgan TR
Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
[TBL] [Abstract][Full Text] [Related]
36. Immune cell-mediated features of non-alcoholic steatohepatitis.
Huby T; Gautier EL
Nat Rev Immunol; 2022 Jul; 22(7):429-443. PubMed ID: 34741169
[TBL] [Abstract][Full Text] [Related]
37. Adaptive immunity: an emerging player in the progression of NAFLD.
Sutti S; Albano E
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
[TBL] [Abstract][Full Text] [Related]
38. Hepatic inflammatory responses in liver fibrosis.
Hammerich L; Tacke F
Nat Rev Gastroenterol Hepatol; 2023 Oct; 20(10):633-646. PubMed ID: 37400694
[TBL] [Abstract][Full Text] [Related]
39. The diagnosis and treatment of non-alcoholic fatty liver disease.
Altinbas A; Sowa JP; Hasenberg T; Canbay A
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
[TBL] [Abstract][Full Text] [Related]
40. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
Zhou L; Shen H; Li X; Wang H
Front Immunol; 2022; 13():951406. PubMed ID: 35958574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
